KIT突变与微小残留病联合对t(8;21)急性髓系白血病预后的影响。 - Suppr

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.

作者信息

Qin Ya-Zhen, Jiang Qian, Wang Yu, Jiang Hao, Xu Lan-Ping, Zhao Xiao-Su, Zhang Xiao-Hui, Liu Kai-Yan, Huang Xiao-Jun

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

出版信息

Blood Cancer J. 2021 Apr 1;11(4):67. doi: 10.1038/s41408-021-00461-z.

DOI:10.1038/s41408-021-00461-z

PMID:33795645

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8016839/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd30/8016839/76213596d966/41408_2021_461_Fig1_HTML.jpg

相似文献

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.KIT突变与微小残留病联合对t(8;21)急性髓系白血病预后的影响。

Blood Cancer J. 2021 Apr 1;11(4):67. doi: 10.1038/s41408-021-00461-z.

Minimal residual disease-directed therapy in acute myeloid leukemia.急性髓系白血病的微小残留病导向治疗

Blood. 2015 Apr 9;125(15):2331-5. doi: 10.1182/blood-2014-11-578815. Epub 2015 Jan 28.

Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.异基因造血干细胞移植可改善基于 MRD 指导治疗的高危儿童 t（8；21）急性髓系白血病首次缓解期的预后。

BMC Cancer. 2020 Jun 15;20(1):553. doi: 10.1186/s12885-020-07043-5.

Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.实时定量聚合酶链反应监测核心结合因子急性髓系白血病微小残留病对移植结果的意义。

Cancer. 2020 May 15;126(10):2183-2192. doi: 10.1002/cncr.32769. Epub 2020 Feb 26.

[Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].阿伐替尼桥接异基因造血干细胞移植治疗7例复发/难治性RUNX1-RUNX1T1阳性且伴有KIT突变的急性髓系白血病的疗效分析

Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):767-771. doi: 10.3760/cma.j.cn121090-20240526-00188.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.诊断时WT1转录水平低预示着接受化疗或异基因造血干细胞移植的t(8;21)急性髓系白血病患者预后不良。

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.监测移植后作为微小残留病的CBFB-MYH11，而非KIT突变，可预测成人inv(16)急性髓系白血病异基因造血细胞移植后的复发。

Br J Haematol. 2018 Feb;180(3):448-451. doi: 10.1111/bjh.14340. Epub 2016 Sep 21.

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.异基因造血干细胞移植后RUNX1-RUNX1T1转录水平的动态变化可预测t(8;21)急性髓系白血病患者的复发情况。

J Hematol Oncol. 2017 Feb 6;10(1):44. doi: 10.1186/s13045-017-0414-2.

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.在 t(8;21)AML 成人患者中，基于移植后 RUNX1/RUNX1T1 的 MRD 监测而非 c-KIT 突变，可进行进一步的风险分层。

Blood. 2014 Sep 18;124(12):1880-6. doi: 10.1182/blood-2014-03-563403.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.伴 t(8;21)(q22;q22.1)的急性髓系白血病的可测量残留病监测：来自 AML 研究组的结果。

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

引用本文的文献

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission. measurable residual disease 结合 CD19 对成人 t(8;21) 急性髓系白血病首次完全缓解后缓解后治疗选择的影响。

Cancer Med. 2024 Feb;13(4):e7074. doi: 10.1002/cam4.7074.

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study.一项多中心前瞻性队列研究表明，基于遗传学和微小残留病（MRD）的风险导向治疗可改善AML1-ETO阳性急性髓系白血病（AML）患者的预后。

Blood Cancer J. 2023 Nov 13;13(1):168. doi: 10.1038/s41408-023-00941-4.

Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.阿伐普替尼对异基因造血干细胞移植后接受免疫治疗失败的伴有t(8;21)和试剂盒突变的急性髓系白血病微小残留病有效。

Bone Marrow Transplant. 2023 Jul;58(7):777-783. doi: 10.1038/s41409-023-01973-x. Epub 2023 Apr 6.

Int J Hematol Oncol. 2023 Feb 14;12(1):IJH43. doi: 10.2217/ijh-2022-0004. eCollection 2023 Feb.

[Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia].[t(8;21)急性髓系白血病患者异基因造血干细胞移植后复发的危险因素分析]

Zhonghua Xue Ye Xue Za Zhi. 2021 Dec 14;42(12):998-1004. doi: 10.3760/cma.j.issn.0253-2727.2021.12.006.

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.中华血液学分会关于异基因造血干细胞移植适应证、预处理方案及供者选择的专家共识（2021 年版）

J Hematol Oncol. 2021 Sep 15;14(1):145. doi: 10.1186/s13045-021-01159-2.

本文引用的文献

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.核心结合因子急性髓系白血病的基因组异质性及其临床意义。

Blood Adv. 2020 Dec 22;4(24):6342-6352. doi: 10.1182/bloodadvances.2020002673.

The clinical mutatome of core binding factor leukemia.核心结合因子白血病的临床突变组学。

Leukemia. 2020 Jun;34(6):1553-1562. doi: 10.1038/s41375-019-0697-0. Epub 2020 Jan 2.

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.伴 t(8;21)的急性髓系白血病的基因组图谱和克隆进化：331 例患者的国际研究。

Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4.

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21).伴有t(8;21)的成人急性髓系白血病患者中KIT突变类型的异质性预后。

Blood Cancer J. 2018 Aug 7;8(8):76. doi: 10.1038/s41408-018-0116-1.

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.中国血液学会关于血液系统疾病异基因造血细胞移植适应证、预处理方案及供者选择的共识。

J Hematol Oncol. 2018 Mar 2;11(1):33. doi: 10.1186/s13045-018-0564-x.

J Hematol Oncol. 2017 Feb 6;10(1):44. doi: 10.1186/s13045-017-0414-2.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.核心结合因子急性髓系白血病的全面突变谱分析

Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.MRD 导向的危险分层治疗可能改善首次完全缓解时 t(8;21) AML 的结局：来自 AML05 多中心试验的结果。

Blood. 2013 May 16;121(20):4056-62. doi: 10.1182/blood-2012-11-468348. Epub 2013 Mar 27.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献